Subscription Required

Only paid subscribers* to Drug Benefit News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Drug Benefit News receive

  • 24 biweekly issues (8 pages) of timely news and insightful strategies for reducing costs and improving outcomes, delivered First Class by U.S. Mail and electronically
  • Special E-Alerts when timely news breaks
  • Access to your subscriber-only web page with:
    • A posting of the latest issue
    • Searchable archives of all articles for the past three years
    • A chronological posting of back issues for three years
  • Recent stories of interest and hot topic articles grouped for convenient reading and regular postings from your editor
View a sample and get more information
July 25, 2014

Recent Stories of Interest

From Drug Benefit News - The practice of 340B covered entities engaging in contract pharmacy arrangements has come under increasing scrutiny since a February study report from the HHS Office of Inspector General (OIG) uncovered certain inconsistencies in the federal drug pricing program. Two new reports call attention to program integrity issues caused by the rapid expansion of 340B pharmacy networks, which may lead to duplicate discounts being paid to 340B entities and commercial and/or Medicaid plans. Read more

Nearly two years after Novartis lost its patents on the popular hypertension… Read more

While PBMs have been giving significant attention to the rising cost of… Read more

From the Editor

Welcome to your Drug Benefit News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with comments on the last issue of Drug Benefit News, story ideas for future issues or any other suggestions you have that can make the newsletter more useful for you.

July 24, 2014
FDA Accepts Sandoz’s Biosimilar Filgrastim Application

Sandoz says FDA has accepted its application for biosimilar filgrastim; company is first to file a biologic application under the biosimilar pathway

July 18, 2014
Clone of Shire Agrees to Acquisition by AbbVie

On fifth attempt, Shire finally agrees to be purchased by AbbVie; deal is worth nearly $55 billion and is expected to close in the fourth quarter. Shire will move corporate tax headquarters to Britain

July 15, 2014
Compounding Industry Launches Counterattack on PBMs

Compounding industry launches counterattack on PBMs' efforts to limit compounded meds.

Updated Regularly

Featured Hot Topics

Search for your own Hot Topics

It's quick and easy to sign up for FREE access to!

Why do I need to register?